相关实验视频

Updated: May 24, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

在瑞典的现实环境中,与SLE中药物的有效性和安全性相关的贝利穆马布度和免疫性

Alvaro Gomez¹, Tomas Walhelm², Floris C Loeff³

¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

Rheumatology (Oxford, England)

|March 4, 2025

概括

在SLE患者中,贝利马布治疗没有显示免疫性,并且药物水平随着时间的推移而稳定. 较高的贝利马布度与改善的临床结果有轻微的联系,但与血清学标志物或不良事件无关.

科学领域:

免疫学免疫学免疫学
类风湿病学类风湿病学
药理学药理学是指药理学的学科.

背景情况:

治疗药物监测 (TDM) 对于生物制药在系统性红斑狼 (SLE) 的研究不足.
贝利马布是一种用于治疗SLE的生物药物.
评估药物水平和免疫性对于优化治疗至关重要.

研究的目的:

评估使用贝利姆巴治疗SLE患者的抗药抗体 (ADA) 发生情况.
调查贝利穆马布度与临床反应,血清学标志物和不良事件之间的关联.

主要方法:

研究了100名接受静脉注射贝利姆巴的SLE患者.
使用ELISA和放射性免疫检测测法测量了贝利马布水平和ADA.
临床活性 (SLEDAI-2K,SLAM-R,PhGA) 和血清学标记 (C3,C4,抗dsDNA) 被纵向评估.

主要成果:

贝利穆马布度有很大的变化,但随着时间的推移保持稳定;没有患者出现ADA.
在6个月后,贝利马布水平与临床疾病活性评分 (SLEDAI-2K,PhGA) 有适度的相关性.
纵向分析显示,贝利马布水平与临床活性 (SLEDAI-2K,SLAM-R) 之间存在微弱的关联,与血清学标记或不良事件无关.

结论:

贝利马布在这个患者队列中没有表现出免疫性.
贝利马布水平与SLE患者的临床改善有着适度的关联.
贝利穆马布的TDM可能会带来临床益处,但它对血清学标志物和安全性的影响需要进一步调查.

关键词:

B 细胞 B 细胞 B 细胞这就是B型淋巴细胞.对抗药物抗体的抗体.贝利姆巴姆巴姆是什么意思生物学的生物学.免疫性免疫性免疫性系统性红血性狼 (Systemic Lupus Erythematosus) 是一种全身性狼.治疗监测治疗监测

更多相关视频

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...